{"groups":[{"description":"Patients receive glutaminase inhibitor CB-839 PO BID on days 1-28 and azacitidine SC or IV over 10-40 minutes on days 1-7.\n\nAzacitidine: Given IV or SC\n\nGlutaminase Inhibitor CB-839: Given PO","id":"FG000","title":"Treatment (Glutaminase Inhibitor CB-839, Azacitidine)"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"28"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"28"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}